71 articles in this topic
A 260-infant RCT tests whether adding bleomycin injections to low-dose propranolol accelerates hemangioma regression and improves skin outcomes.
A completed trial examines how a key inflammation pathway connects periodontitis stages to the chronic low-grade inflammation of aging.
A landmark effort to bank immune-compatible stem cells matched to the majority of the US population — now terminated.
A phase 1 dose-escalation trial tests the safety of AAV-delivered ND4 gene therapy in patients with Leber's hereditary optic neuropathy.
NHLBI researchers optimize collection and storage of umbilical cord blood from sickle cell-affected and healthy newborns for future stem cell therapies.
A Phase 1/2 trial of NFS-02 gene therapy for LHON-associated vision loss was terminated before completion, raising questions about mitochondrial gene therapy.
A completed multicenter feasibility trial evaluates BTM, a novel biodegradable scaffold, for treating serious deep burn injuries.
A 12-month RCT compares three scaffold types and two EDTA concentrations for regenerating necrotic immature permanent teeth.
The landmark Phase 1/2/3 trial that brought mRNA COVID-19 vaccination to the world, now completed with booster and variant data.
NIDCR researchers compared stromal cells from bone marrow, skin, spleen, and fat to identify which best regenerates bone and supports blood formation.
A terminated RCT explored whether immunotype-targeted supplements could reduce iAge®, an AI-derived biomarker of chronic inflammation and immune aging.
A Phase 3 trial evaluates a next-generation quadrivalent influenza vaccine against existing options, testing both immune response and manufacturing consistency.
